{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:21:01Z","timestamp":1793262061243,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG08\/008"],"award-info":[{"award-number":["RG08\/008"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR134993"],"award-info":[{"award-number":["NIHR134993"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.atherosclerosis.2024.118598","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T21:36:03Z","timestamp":1727559363000},"page":"118598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials"],"prefix":"10.1016","volume":"401","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5136","authenticated-orcid":false,"given":"Alexis","family":"Llewellyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Harden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve E.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Priestley-Barnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila J.","family":"Tata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118598_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"issue":"36","key":"10.1016\/j.atherosclerosis.2024.118598_bib2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118598_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2018.04.040","article-title":"Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register","volume":"274","author":"Humphries","year":"2018","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118598_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2012.10.032","article-title":"Statin treatment of children with familial hypercholesterolemia\u2013trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?","volume":"226","author":"Vuorio","year":"2013","journal-title":"Atherosclerosis"},{"issue":"32","key":"10.1016\/j.atherosclerosis.2024.118598_bib6","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118598_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2024.118598_bib8","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.09.005","article-title":"Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care","volume":"290","author":"Ramaswami","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib10","series-title":"Clinical Guideline [CG71]","article-title":"Familial hypercholesterolaemia: identification and management","year":"2019"},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib11","series-title":"Summary of Product Characteristics - Praluent","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib12","series-title":"Summary of Product Characteristics - Repatha","year":"2015"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118598_bib13","article-title":"Statins for children with familial hypercholesterolemia","author":"Vuorio","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2020.10.132","article-title":"Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials","volume":"315","author":"Anagnostis","year":"2020","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118598_bib15","first-page":"810","article-title":"Statin treatments and dosages in children with familial hypercholesterolemia: meta-analysis","volume":"111","author":"Radaelli","year":"2018","journal-title":"Arq. Bras. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118598_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia","volume":"166","author":"Kusters","year":"2015","journal-title":"J. Pediatr."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2024.118598_bib17","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jacc.2008.09.002","article-title":"Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia","volume":"52","author":"van der Graaf","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118598_bib18","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias","year":"2019","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib19","series-title":"Research Award NIHR134993: Lipid-Modifying Therapy in Children with Familial Hypercholesterolemia","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib20","series-title":"Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care","year":"2009"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118598_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib22","article-title":"Effectiveness and safety of statins and ezetimibe for children and adolescents with heterozygous familial hypercholesterolaemia: systematic review and meta-analysis","author":"Llewellyn","year":"2023","journal-title":"PROSPERO"},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib23","series-title":"Lipid Modification - CVD Prevention: Scenario: Lipid Therapy - Primary Prevention of CVD","year":"2023"},{"issue":"7404","key":"10.1016\/j.atherosclerosis.2024.118598_bib24","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118598_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12020-020-02302-8","article-title":"Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials","volume":"69","author":"Anagnostis","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib26","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118598_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2307\/2982993","article-title":"Publication bias: a problem in interpreting medical data","volume":"151","author":"Begg","year":"1988","journal-title":"J. Roy. Stat. Soc. Stat. Soc."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.118598_bib28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib29","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118598_bib30","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jacc.2009.10.042","article-title":"Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia","volume":"55","author":"Avis","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118598_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.05.006","article-title":"Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk","volume":"167","author":"Braamskamp","year":"2015","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118598_bib32","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1542\/peds.2004-2090","article-title":"Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia","volume":"116","author":"Clauss","year":"2005","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118598_bib33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.ATV.18.6.1007","article-title":"Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia","volume":"18","author":"Couture","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2024.118598_bib34","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.0000035247.42888.82","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin","volume":"106","author":"de Jongh","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118598_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5551\/jat.28753","article-title":"Efficacy and safety of pitavastatin in Japanese male children with familial hypercholesterolemia","volume":"23","author":"Harada-Shiba","year":"2016","journal-title":"J. Atherosclerosis Thromb."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118598_bib36","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1203\/00006450-199605000-00021","article-title":"Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia","volume":"39","author":"Knipscheer","year":"1996","journal-title":"Pediatr. Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118598_bib37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1542\/peds.97.5.619","article-title":"Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group","volume":"97","author":"Lambert","year":"1996","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118598_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3476(03)00186-0","article-title":"Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial","volume":"143","author":"McCrindle","year":"2003","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118598_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.281.2.137","article-title":"Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial","volume":"281","author":"Stein","year":"1999","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2024.118598_bib40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118598_bib41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/CIRCULATIONAHA.116.025158","article-title":"Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (hypercholesterolemia in children and adolescents taking rosuvastatin open label)","volume":"136","author":"Braamskamp","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118598_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-116-1-78","article-title":"A consumer's guide to subgroup analyses","volume":"116","author":"Oxman","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib43","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2019.11.012","article-title":"Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries","volume":"292","author":"Ramaswami","year":"2020","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118598_bib44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacl.2015.07.011","article-title":"Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study","volume":"9","author":"Braamskamp","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-1182-5","article-title":"Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature","volume":"19","author":"Yu","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2024.118598_bib46","article-title":"Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues","volume":"6","author":"Langslet","year":"2021","journal-title":"Am. J. Prev. Cardiol."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2024.118598_bib47","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","article-title":"Evolocumab in pediatric heterozygous familial hypercholesterolemia","volume":"383","author":"Santos","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118598_bib48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamapediatrics.2023.6477","article-title":"Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"178","author":"Santos","year":"2024","journal-title":"JAMA Pediatr."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024011705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024011705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T05:49:08Z","timestamp":1741844948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024011705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":48,"alternative-id":["S0021915024011705"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118598","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"118598"}}